January 2019 in “Springer eBooks” Combination therapies might work better for some vitiligo patients, but results vary.
January 2022 in “Clinical Cases in Dermatology” A woman has a permanent hair loss condition treated with steroids and new medicines, but hair might not regrow.
June 2024 in “Bőrgyógyászati és Venerológiai Szemle” New treatments for hair loss, like JAK inhibitors, PRP, anti-androgens, and minoxidil, offer better options.
1 citations,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.
11 citations,
December 2018 in “Journal of the European Academy of Dermatology and Venereology” Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
2 citations,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
56 citations,
January 2019 in “Lancet” JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.
7 citations,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
3 citations,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
November 2020 in “Journal of The American Academy of Dermatology” Oral JAK inhibitors help regrow hair in alopecia patients.
November 2017 in “Asian journal of pharmaceutical and clinical research” Three compounds from Dadap leaves may help treat hair loss.
December 2017 in “Annales de dermatologie et de vénéréologie” In 2017, pediatric dermatology advanced with new treatments and insights into various skin conditions in children.
16 citations,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
116 citations,
February 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors help with skin conditions but need more research on dosing and safety.
49 citations,
August 2018 in “International Journal of Dermatology” Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
4 citations,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
2 citations,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
March 2017 in “Current dermatology reports” Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
October 2021 in “International Journal of Dermatology” JAK inhibitors do not improve hair regrowth in androgenic alopecia but may prevent further hair loss.
63 citations,
July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
September 2023 in “JAAD case reports” A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
April 2023 in “Revista colombiana de reumatología” JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
April 2017 in “Australasian Journal of Dermatology” The session covered updates on skin treatments, including radiotherapy, imiquimod, acitretin, JAK inhibitors, and strategies for managing rosacea and preventing surgical infections.
77 citations,
June 2017 in “Advances in Therapy” New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
6 citations,
March 2016 in “Scandinavian journal of immunology” Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
2 citations,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
1 citations,
December 2023 in “Molecules/Molecules online/Molecules annual” JAK inhibitors show promise for treating various skin diseases.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
October 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” A protein called EGFR protects hair follicle stem cells, and when it's disrupted, hair follicles can be damaged, but blocking certain pathways can restore hair growth.
February 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors may help treat alopecia areata by reversing hair loss.